Evaluation of chemiluminescence, toluidine blue and histopathology for detection of high risk oral precancerous lesions: A cross-sectional study

BMC Clinical Pathology

Manju Mamtani⁴  Tushar P Thakre²  Vinay Hazarey¹  Minal Chaudhary³  Prajakta Zade¹  Vijay Wadhwan³  Shirish Degwekar³  Mukta B Motwani³  Shweta Ujaoney³ 

[1] Government Dental College & Hospital, Nagpur, India;Lata Medical Research Foundation, Nagpur, India;Sharad Pawar Dental College & Hospital, Sawangi (Meghe), Wardha, India;12023 Waterway Rdg, San Antonio, TX 78249, USA

关键词: light-based methods;    Screening;    Leukoplakia;    Oral cancer;   

Others  :  1085431
DOI  :  10.1186/1472-6890-12-6

 received in 2011-07-08, accepted in 2012-03-12,  发布年份 2012

【 摘 要 】

Background

Early detection holds the key to an effective control of cancers in general and of oral cancers in particular. However, screening procedures for oral cancer are not straightforward due to procedural requirements as well as feasibility issues, especially in resource-limited countries.

Methods

We conducted a cross-sectional study to compare the performance of chemiluminescence, toluidine blue and histopathology for detection of high-risk precancerous oral lesions. We evaluated 99 lesions from 55 patients who underwent chemiluminescence and toluidine blue tests along with biopsy and histopathological examination. We studied inter-as well as intra-rater agreement in the histopathological evaluation and then using latent class modeling, we estimated the operating characteristics of these tests in the absence of a reference standard test.

Results

There was a weak inter-rater agreement (kappa < 0.15) as well as a weak intra-rater reproducibility (Pearson's r = 0.28, intra-class correlation rho = 0.03) in the histopathological evaluation of potentially high-risk precancerous lesions. When compared to histopathology, chemiluminescence and toluidine blue retention had a sensitivity of 1.00 and 0.59, respectively and a specificity of 0.01 and 0.79, respectively. However, latent class analysis indicated a low sensitivity (0.37) and high specificity (0.90) of histopathological evaluation. Toluidine blue had a near perfect high sensitivity and specificity for detection of high-risk lesions.

Conclusion

In our study, there was variability in the histopathological evaluation of oral precancerous lesions. Our results indicate that toluidine blue retention test may be better suited than chemiluminescence to detect high-risk oral precancerous lesions in a high-prevalence and low-resource setting like India.

【 授权许可】

   
2012 Ujaoney et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Mignogna MD, Fedele S, Lo Russo L: The World Cancer Report and the burden of oral cancer. Eur J Cancer Prev 2004, 13(2):139-142.
• [2]Petersen PE: Oral cancer prevention and control-the approach of the World Health Organization. Oral Oncol 2009, 45(4-5):454-460.
• [3]Mehrotra R, Singh M, Thomas S, Nair P, Pandya S, Nigam NS, Shukla P: A cross-sectional study evaluating chemiluminescence and autofluorescence in the detection of clinically innocuous precancerous and cancerous oral lesions. J Am Dent Assoc 2010, 141(2):151-156.
• [4]Yeole BB, Sankaranarayanan R, Sunny MSL, Swaminathan R, Parkin DM: Survival from head and neck cancer in Mumbai (Bombay), India. Cancer 2000, 89(2):437-444.
• [5]Sankaranarayanan R: Screening for cervical and oral cancers in India is feasible and effective. Natl Med J India 2005, 18(6):281-284.
• [6]Sankaranarayanan R, Boffetta P: Research on cancer prevention, detection and management in low- and medium-income countries. Ann Oncol 2010, 21(10):1935-1943.
• [7]Sankaranarayanan R, Dinshaw K, Nene BM, Ramadas K, Esmy PO, Jayant K, Somanathan T, Shastri S: Cervical and oral cancer screening in India. J Med Screen 2006, 13(Suppl 1):S35-S38.
• [8]Sankaranarayanan R, Mathew B, Jacob BJ, Thomas G, Somanathan T, Pisani P, Pandey M, Ramadas K, Najeeb K, Abraham E: Early findings from a community-based, cluster-randomized, controlled oral cancer screening trial in Kerala, India. The Trivandrum Oral Cancer Screening Study Group. Cancer 2000, 88(3):664-673.
• [9]Trullenque-Eriksson A, Munoz-Corcuera M, Campo-Trapero J, Cano-Sanchez J, Bascones-Martinez A: Analysis of new diagnostic methods in suspicious lesions of the oral mucosa. Med Oral Patol Oral Cir Bucal 2009, 14(5):E210-E216.
• [10]Patton LL, Epstein JB, Kerr AR: Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. J Am Dent Assoc 2008, 139(7):896-905. quiz 993-894
• [11]Sciubba JJ: Improving detection of precancerous and cancerous oral lesions. Computer-assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. J Am Dent Assoc 1999, 130(10):1445-1457.
• [12]Brandwein-Gensler M, Smith RV, Wang B, Penner C, Theilken A, Broughel D, Schiff B, Owen RP, Smith J, Sarta C, et al.: Validation of the histologic risk model in a new cohort of patients with head and neck squamous cell carcinoma. Am J Surg Pathol 2010, 34(5):676-688.
• [13]Kerr AR, Sirois DA, Epstein JB: Clinical evaluation of chemiluminescent lighting: an adjunct for oral mucosal examinations. J Clin Dent 2006, 17(3):59-63.
• [14]Ram S, Siar CH: Chemiluminescence as a diagnostic aid in the detection of oral cancer and potentially malignant epithelial lesions. Int J Oral Maxillofac Surg 2005, 34(5):521-527.
• [15]Huff KD: More about cancer detection. J Am Dent Assoc 2010, 141(6):626-628. author reply 628, 630
• [16]Truelove EL: Detecting oral cancer. J Am Dent Assoc 2010, 141(6):626. author reply 628, 630
• [17]Oliver RJ, MacDonald DG, Felix DH: Aspects of cell proliferation in oral epithelial dysplastic lesions. J Oral Pathol Med 2000, 29(2):49-55.
• [18]Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E: Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008, 37(3):127-133.
• [19]Dendukuri N, Hadgu A, Wang L: Modeling conditional dependence between diagnostic tests: a multiple latent variable model. Stat Med 2009, 28(3):441-461.
• [20]Ihorst G, Forster J, Petersen G, Werchau H, Rohwedder A, Schumacher M: The use of imperfect diagnostic tests had an impact on prevalence estimation. J Clin Epidemiol 2007, 60(9):902-910.
• [21]Koukounari A, Webster JP, Donnelly CA, Bray BC, Naples J, Bosompem K, Shiff C: Sensitivities and specificities of diagnostic tests and infection prevalence of Schistosoma haematobium estimated from data on adults in villages northwest of Accra, Ghana. Am J Trop Med Hyg 2009, 80(3):435-441.
• [22]Yang I, Becker MP: Latent variable modeling of diagnostic accuracy. Biometrics 1997, 53(3):948-958.
• [23]Bertrand P, Benichou J, Grenier P, Chastang C: Hui and Walter's latent-class reference-free approach may be more useful in assessing agreement than diagnostic performance. J Clin Epidemiol 2005, 58(7):688-700.
• [24]Albert PS, Dodd LE: On Estimating Diagnostic Accuracy From Studies With Multiple Raters and Partial Gold Standard Evaluation. J Am Stat Assoc 2008, 103(481):61-73.
• [25]Baughman AL, Bisgard KM, Cortese MM, Thompson WW, Sanden GN, Strebel PM: Utility of composite reference standards and latent class analysis in evaluating the clinical accuracy of diagnostic tests for pertussis. Clin Vaccine Immunol 2008, 15(1):106-114.
• [26]Chu H, Zhou Y, Cole SR, Ibrahim JG: On the estimation of disease prevalence by latent class models for screening studies using two screening tests with categorical disease status verified in test positives only. Stat Med 2010, 29(11):1206-1218.
• [27]Toft N, Jorgensen E, Hojsgaard S: Diagnosing diagnostic tests: evaluating the assumptions underlying the estimation of sensitivity and specificity in the absence of a gold standard. Prev Vet Med 2005, 68(1):19-33.
• [28]Rana M, Zapf A, Kuehle M, Gellrich NC, Eckardt AM: Clinical evaluation of an autofluorescence diagnostic device for oral cancer detection: a prospective randomized diagnostic study. Eur J Cancer Prev 2012. doi: 10.1097/CEJ.0b013e32834fdb6d
• [29]Awan KH, Morgan PR, Warnakulasuriya S: Evaluation of an autofluorescence based imaging system (VELscope) in the detection of oral potentially malignant disorders and benign keratoses. Oral Oncol 2011, 47(4):274-277.
• [30]Driemel O, Kunkel M, Hullmann M, von Eggeling F, Muller-Richter U, Kosmehl H, Reichert TE: Diagnosis of oral squamous cell carcinoma and its precursor lesions. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG 2007, 5(12):1095-1100.
• [31]Seoane Leston J, Diz Dios P: Diagnostic clinical aids in oral cancer. Oral Oncol 2010, 46(6):418-422.
• [32]Epstein JB, Silverman S Jr, Epstein JD, Lonky SA, Bride MA: Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue. Oral Oncol 2008, 44(6):538-544.
• [33]Guneri P, Epstein JB, Kaya A, Veral A, Kazandi A, Boyacioglu H: The utility of toluidine blue staining and brush cytology as adjuncts in clinical examination of suspicious oral mucosal lesions. Int J Oral Maxillofac Surg 2011, 40(2):155-161.
• [34]Epstein JB, Guneri P: The adjunctive role of toluidine blue in detection of oral premalignant and malignant lesions. Current opinion in otolaryngology & head and neck surgery 2009, 17(2):79-87.
• [35]Patton LL: The effectiveness of community-based visual screening and utility of adjunctive diagnostic aids in the early detection of oral cancer. Oral Oncol 2003, 39(7):708-723.